髓原抑制细胞上的MARCO表达对于它们的分化和免疫抑制至关重要
Sijia Liu1, Binle Tian2,3, Na Wang4
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Cell death discovery
|July 22, 2025
概括
具有原结构的巨细胞受体 (MARCO) 通过促进髓质衍生抑制细胞 (MDSCs) 来驱动乳腺癌的免疫抑制. 用抗体针对MARCO,单独或与PD-1阻断一起,抑制瘤生长并增强抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
背景情况:
- 骨髓系衍生抑制细胞 (MDSCs) 创造了一个免疫抑制瘤微环境 (TME).
- 准MDSC是一种有前途的癌症免疫治疗策略.
- 大细胞受体与原结构 (MARCO) 在MDSC调节中的作用尚未被探索.
研究的目的:
- 调查MARCO在乳腺癌中MDSC分化和免疫抑制中的作用.
- 评估MARCO作为癌症免疫治疗的治疗标.
主要方法:
- 在MDSCs上对MARCO的表达式分析.
- 利用乳腺瘤衍生的外体细胞 (TDE) 来研究MDSC调节.
- 采用一种带有遗传 MARCO 切除的小鼠乳腺癌模型.
- 开发和测试一种MARCO降调单克隆抗体.
- 评估与PD-1阻断的联合治疗.
主要成果:
- 在MDSC上,MARCO通过富含巨细胞迁移抑制因子 (MIF) 的TDE上调,增强免疫抑制.
- 在小鼠中,遗传MARCO切除减少了瘤生长,M-MDSC和TAM,同时增加了CD8+T细胞和NK细胞的透.
- 马可降低调控抗体治疗抑制了瘤生长并逆转了TME免疫抑制.
- 与MARCO抗体和PD-1阻断的联合治疗显示出协同作用的抗瘤效应.
结论:
- 马可是乳腺癌中MDSC介导免疫抑制的关键调节剂.
- 向MARCO代表了癌症免疫治疗的新治疗策略.
- 针对MARCO的治疗方法,特别是与检查点抑制剂相结合,具有显著的潜力,可以提高抗瘤疗效.
相关概念视频
01:15Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
01:24B Cell Activation and Differentiation
6.1K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
6.1K
01:01Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
02:23Master Transcription Regulators
7.1K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.1K
01:21Lineage Commitment
3.1K
Commitment is the process whereby stem cells:
3.1K
01:19Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K